Drug maker AstraZeneca’s Seroquel gets U.S. FDA approval
Advertisement
Read this article for free:
or
Already have an account? Log in here »
To continue reading, please subscribe:
Monthly Digital Subscription
$1 per week for 24 weeks*
- Enjoy unlimited reading on winnipegfreepress.com
- Read the E-Edition, our digital replica newspaper
- Access News Break, our award-winning app
- Play interactive puzzles
*Billed as $4.00 plus GST every four weeks. After 24 weeks, price increases to the regular rate of $19.95 plus GST every four weeks. Offer available to new and qualified returning subscribers only. Cancel any time.
Monthly Digital Subscription
$4.99/week*
- Enjoy unlimited reading on winnipegfreepress.com
- Read the E-Edition, our digital replica newspaper
- Access News Break, our award-winning app
- Play interactive puzzles
*Billed as $19.95 plus GST every four weeks. Cancel any time.
To continue reading, please subscribe:
Add Free Press access to your Brandon Sun subscription for only an additional
$1 for the first 4 weeks*
*Your next subscription payment will increase by $1.00 and you will be charged $16.99 plus GST for four weeks. After four weeks, your payment will increase to $23.99 plus GST every four weeks.
Read unlimited articles for free today:
or
Already have an account? Log in here »
Hey there, time traveller!
This article was published 14/05/2008 (6544 days ago), so information in it may no longer be current.
LONDON – AstraZeneca PLC said Wednesday that U.S. regulators have approved its anti-psychotic drug Seroquel as a maintenance treatment for patients with a type of bipolar disorder.
Seroquel, already on sale to treat schizophrenia and depressive or manic episodes, is AstraZeneca’s second-biggest selling drug, generating $4 billion of sales in 2007, but it is facing strong potential generic competition.
The new ruling from the U.S. Food and Drug Administration means that patients may take the drug as an adjunct to the already widely used medicines lithium and divalproex for maintenance treatment of bipolar I disorder.
AstraZeneca said bipolar disorder currently affects about eight million adults in the United States.
Bipolar I disorder is a severe, lifelong form of mental illness characterized by severe mood swings ranging from mania to major depression that will affect between 0.4 per cent to 1.6 per cent of people over their lifetime.
Shares in AstraZeneca, which is facing the prospect of strong generic competition to Seroquel, rose 1.3 per cent to 2,118 pence ($41.05) after the announcement.
WestLB analyst Simon Mather said the FDA approval was positive, but did not expect it to have “any major impact on the share price,” noting that the ongoing patent struggle between AstraZeneca and Teva Pharmaceutical Industries Ltd. and Novartis AG’s Sandoz Inc. unit is more important.
Teva and Sandoz have applied for approval to market cheaper versions of Seroquel in the U.S. before a key patent expires in 2011.
Mather said that if AstraZeneca is successful in defending the patent surrounding Seroquel and the issue is resolved at a summary judgment hearing in June, “we would expect a much greater share price reaction.”
In the meantime, AstraZeneca is working hard to promote a follow-on, extended release version of the drug called Seroquel XR, to protect its sales.
It has also asked European regulators to approve the drug’s use for the maintenance treatment of bipolar I disorder.
AstraZeneca sued Teva, the world’s biggest generic drug maker, in 2005 to block a cheaper form of Seroquel. It sued Sandoz, the world’s second biggest generic drug company, last year when it applied to sell Seroquel copies in four different doses.